|
Programs |
|
|
| Platform Partnerships |
Multidisciplinary
Research Training
and Team Development |
| Nanotechnology Characterization Laboratory (NCL) |
|
|
MIT-Harvard Center of Cancer Nanotechnology
Massachusetts Institute of Technology and Harvard University CCNE
The overall goal of this U54 application is to create and support a highly multidisciplinary team of chemists, biologists, engineers and physicians to develop and rapidly translate new nanotechnologies to better diagnose and treat cancer. The current team includes investigators from Massachusetts Institute of Technology (MIT), Harvard Faculty of Arts and Sciences (FAS), Harvard Medical School (HMS), Massachusetts General Hospital (MGH), and Brigham and Women's Hospital (BWH). Specific applications of nanotechnology in this application include targeted therapies, diagnostics, noninvasive imaging, and molecular sensing.
Project 1 (Langer, Farokhazad) is developing novel nanoparticles for cancer targeting using prostate cancer as a model. Project 2 (Sharp, Bhatia) is developing new siRNA delivery and targeting strategies for use in treatment of cancer (lung and brain cancers will serve as models). Project 3 (Weissleder, Josephson) is developing clinically viable, next-generation magnetic nanoparticles for targeted multimodal imaging of cancer. Project 4 (Cima) is creating unique miniaturized MEMS-based devices for molecular sensing. Project 5 (Belcher, Bawendi) is developing and applying novel semiconductor nanocrystals for biomedical sensing in the context of cancer. In the first year, up to eight pilot projects are being developed as a means of attracting new investigators to the consortium, to stimulate creative, high-impact research, to rapidly test new nanomaterials, and to fund collaborative work. The Projects and Pilot Projects are supported by a Toxicity Core and a Mouse Models Core. It is anticipated that this research in nanotechnology will significantly advance medical science and treatment of cancer.
|
